Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Respiratory distress syndrome is also known as hyaline membrane disease, which is the most common respiratory disorder in preterm infants. The primary cause of respiratory distress syndrome is inadequate pulmonary surfactant. Symptoms of respiratory distress syndrome are shortness of breath, nasal flaring, and grunting. RDS is manifested immediately or after 4 hours of birth. The management of respiratory distress syndrome can be achieved by antenatal glucocorticoids, continuous positive air pressure (CPAP), positive end expiratory pressure, and surfactant replacement therapy. According to UCSF Medical Centre, RDS affects 40,000 infants each year in the U.S. and accounts for approximately 20% of neonatal deaths.

Global Respiratory Distress Syndrome Treatment Market - Drivers

There has been significant developments in the field of healthcare, which have created opportunities for respiratory distress syndrome market in the past decade. In 2015, the World Health Organization (WHO) recommended surfactant replacement therapy for neonatal respiratory distress syndrome as an efficient treatment. According to National Organization of Rare Disease, respiratory distress syndrome can affect people of any age suffering from lung injury, Globally 306 persons are affected in 100,000 persons among age 75 – 80, Thus, rising prevalence of RDS with high mortality has boosted the market growth. Therefore, pharmaceutical companies are focusing on mergers and acquisitions which is expected to support global respiratory distress syndrome treatment market growth. For instance, in March 2020, Windtree Therapeutics, a biotechnological and medical device company, signed an agreement with Lee’s Pharmaceutical, in which Lee’s Pharmaceutical will provide project financing for AEROSURF, a lead product of Windtree Pharmaceutics.

Global Respiratory Distress Syndrome Treatment Market-Impact of COVID-19

The COVID-19 pandemic is closely associated with symptoms of respiratory distress syndrome. As patients suffering from respiratory distress are at severe risk of COVID-19 infection, doctors have to take efforts to classify patients according to their severity to treat them with ventilatory management or surfactant therapy. Therefore, due to this pandemic, there is significant increase in use of respiratory distress treatments such as surfactant therapy, oxygen therapy, and ventilation support for patients with severe symptoms of COVID-19. Thus, there is positive impact on respiratory distress syndrome treatment market due to this pandemic.

Global Respiratory Distress Syndrome Treatment Market - Restraints

Surfactant therapy is a treatment for respiratory distress, which has short term risks in patients such as bradycardia, hypoxemia during instillation, and may cause blockage in endotracheal tube. Moreover, surfactant used in therapy has very low microbiological stability. Furthermore, in oxygen therapy, patient discomfort is prominently observed and also higher cost of ventilation therapy is an out of pocket expense in middle economic countries. These factors are expected to restrain the global respiratory distress syndrome treatment market growth.

Global Respiratory Distress Syndrome Treatment Market - Regional Analysis

On the basis of region, the global respiratory distress syndrome treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds dominant position in the respiratory distress syndrome treatment market due to higher patient population and high mortality rate due to respiratory distress. For instance, according to U.S National Library of Medicine, In 2017 the incidence of respiratory distress syndrome in the U.S. was 78.9 in 100,000 person. Therefore, pharmaceutical companies are focusing on research and development to deal with the higher incidence in the region. For instance, in 2018, ONY Biotech applied for aerosolized infasurf treatment protocol to U.S Food Drug Administration, which is in pivotal trial currently.

Moreover, in Europe, according to National Library of Medicine, in 2017 the incidence of respiratory distress syndrome was 17.9 in 100,000 person population. After North America, Europe is the second region with highest mortality due to respiratory distress syndrome. Moreover, Europe is also affected negatively due to COVID-19 pandemic, as coronavirus infection is accompanied with respiratory distress symptoms in severe cases. Therefore, pharmaceutical companies are focusing on research and development to find efficient dose regime against SARS-COVID- acute respiratory distress syndrome. For instance, in May 2020 Chiesi Farmaceutici S.P.A started clinical trial on Curosurf for treatment of SARS-COVID- acute respiratory distress syndrome.

Furthermore, Asia Pacific is expected to witness significant growth in the respiratory distress syndrome treatment market. Asia Pacific region is less aware about respiratory distress syndrome but the prevalence of respiratory distress syndrome is moderate. According National Library of Medicine, in 2017 incidence of respiratory distress syndrome in Asia Pacific was 3.04 in 100,000 person. Therefore, pharmaceutical companies are focusing on research and development to achieve growth in the global respiratory distress syndrome market. For instance, in 2018, JW pharmaceuticals, a South Korean company, started marketing ‘infasurf’, which is a drug treatment used for neonatal respiratory distress syndrome.

Global Respiratory Distress Syndrome Treatment Market - Competitive Landscape

Key players operating in the global respiratory distress syndrome treatment market include Chiesi Farmaceutici S.P.A, JW pharmaceuticals, Windtree Therapeutics, Inc, Ony Biotech Inc, AbbVie (NYSE: ABBV), Dey Laboratories Inc , and others.

Key Developments:

  1. In January 2020, Chiesi Farmaceutici S.p.A began clinical trial study of administering surfactant (CUROSURF)in neonates, that will decrease the number of days that infant needs in breathing tube on mechanical ventilator suffering from respiratory distress syndrome
  2. In April 2020, Citus Pharmaceutical Inc announced pre-IND submission to the U.S. Food Drug Administration under Coronavirus Treatment Accelerating Program for Novacite-cells therapy for acute respiratory distress syndrome in COVID-19
  3. In April 2020, Apeptico Forschung und Entwicklung GmbH and OPIS srl announced that the solnatide IMP was approved for patients suffering from COVID-19 accompanied with pulmonary permeability oedema and acute respiratory distress syndrome (ARDS) by the Italian Medicines Agency and the Ethics Committee of the National Institute for Infectious Diseases Lazzaro Spallanzani

Global Respiratory Distress Syndrome Treatment Market - Taxonomy

  • By Treatment Type
    • Surfactant Replacement Therapy
    • Continuous Positive Air Pressure (CPAP)
    • Positive End Expiratory Pressure (PEEP)
    • Antenatal Glucocorticoids
    • Others
  • By Disease Type
    • Adult Respiratory Distress Syndrome
    • Neonatal Respiratory Distress Syndrome
    • By End User
    • Ambulatory Surgical Centers
    • Clinics
    • Hospitals
  • By Region
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
N/A

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Data Triangulation Methodology | Coherent Market Insights

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Market Analysis | Coherent Market Insights

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.